Lilly's EBGLYSS Shows Four-Year Efficacy in Atopic Dermatitis, But Core Incretin Thesis Unaffected

What happened

Eli Lilly announced positive long-term data for EBGLYSS (lebrikizumab-lbkz), showing durable skin clearance and itch relief for up to four years in a Phase 3b study for moderate-to-severe atopic dermatitis, per a PRNewswire release. However, this promotional update should be critically assessed as it lacks details on commercial impact or competitive positioning in immunology, a secondary therapeutic area for Lilly. The DeepValue report indicates Lilly's investment thesis is dominated by its incretin franchise (Mounjaro/Zepbound), which drives earnings but faces net pricing pressure and regulatory risks, leading to a WAIT rating at $985. Key concerns include orforglipron FDA approval timing and sustained volume growth offsetting price declines, with the stock's high valuation embedding optimistic assumptions. Thus, while EBGLYSS data supports pipeline diversification, it does not address the core drivers or alter the fundamental risk-reward profile centered on incretin dynamics.

Implication

The EBGLYSS data may modestly boost confidence in Lilly's R&D execution and provide a future revenue stream, but it is immaterial compared to the incretin franchise's scale and current earnings power. According to the DeepValue report, Lilly's valuation hinges on volume growth countering net price compression, a dynamic unchanged by this immunology news, with risks like orforglipron approval and policy-driven pricing resets looming. The PR nature of the announcement warrants skepticism, as it emphasizes positive outcomes without addressing commercial hurdles or competitive intensity in atopic dermatitis. Critical investment checkpoints remain quarterly gross-to-net disclosures and FDA milestones for orforglipron, which are decisive for the WAIT rating and potential entry points. Therefore, this update does not justify altering exposure or assumptions, reinforcing the need for patience amid crowded narratives and high multiples.

Thesis delta

No material shift in the investment thesis is warranted, as EBGLYSS represents a peripheral asset that does not impact the core incretin-driven valuation or key risk factors. The thesis remains centered on monitoring volume growth versus price declines and orforglipron regulatory progress, with this news merely confirming pipeline diversification without altering earnings projections or risk assessments.